Trending...
- "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience - 326
- New Slotozilla Project Explores What Happens When the World Goes Silent - 262
- Ventura College Launches County's First Speech-Language Pathology Assistant Program - 247
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 11:00 a.m. PST.
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent injectW device in the United States in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent injectW device in the United States in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
- Los Angeles Affordable Healthcare Provider CCHC Reminds Families to Prioritize Vaccines and Wellness for Back-to-School Season
- Meet a Scientologist Makes Magic with Larry Soffer
- ICYMI: California hotline receives 1,200 reports of hate in 2024
- Open Art Call | The Art of Artificial Intelligence | Copenhagen
- Jase has compounded Ivermectin and Mebendazole together to effectively treat parasitic infections!
Filed Under: Business
0 Comments
Latest on The Californer
- 3E Launches First AI Agent Designed to Respond with Empathy for College Recruitment
- Security Alert: TZNXG Warns Investors About "Fund Recovery" Scams
- Assent Unveils Extended Producer Responsibility Packaging Solution to Simplify Compliance with Expanding Packaging Laws
- KatalisCoin: "Too Secure" for Bad Actors - Platform Embraces "Excessive Compliance" Criticism
- Blacksmith Raises $10M to Unblock AI Development with Fast CI for GitHub Actions
- Keyanb Exchange Implements Enhanced Security Protocols Amid Industry-Wide Trust Challenges
- TSWHZC Platform Combines Automated Portfolio Management with Proof of Reserves for Brazil Market Entry
- AureaVault Positions Digital Asset Infrastructure for Shifting Monetary Policy Environment
- JQRBT Unveils High-Speed Trading Infrastructure Designed for Growing Institutional Crypto Market
- TOM HAUSKEN: The Space Between
- California: Governor Newsom announces appointments 9.17.25
- Marketing Maven Ranked Top 10 PR Firm in Los Angeles by O'Dwyer's in 2025 Rankings Report
- California Lutheran University Receives Over $2.9 Million in Grant Funding
- Nationwide Boiler Supplies In-Stock 200K lb/hr Ultra Low NOx Boiler Package for Recovery Efforts i
- Ventura College Foundation Accepting Scholarship Applications for 2026-27 School Year
- C3.ai, Inc. (AI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- California: Governor Newsom proclaims Constitution Day and Citizenship Day
- California: Governor Newsom signs legislation 9.17.25
- New Leadership and Renovations Usher in Next Chapter for Sunrise Manor
- Following Trump's politicization of CDC, West Coast states issue unified vaccine recommendations — California breaks from future federal guidance with new law